ForMune is a newly created spin-off of Digna Biotech based in Navarra, Spain, that develops molecules for subsequent licensing or marketing by pharmaceutical companies. The company has licensed a technology to develop therapeutic vaccines based on the Extra Domain A (EDA) of fibronectin. It intends to use newly raised capital to pursue development of a therapy for neck uterine cancer caused by human papillomavirus (HPV) and for liver infections of Hepatitis B virus (HBV). ForMune raised €4.4M in funding from founding investors that include Navarra Development Society (Sodena) and venture capital firms Inveready and Caja Navarra. The article states the capital will be provided over the next three years. No operating metrics or prior financing rounds are disclosed in the article.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2012